arrow
Return

Vancomycin-Teixobactin Conjugates

delete2025-02-14
delete0
delete
OA
AI
M
Maria Sophia Teresa Lee Padilla
J
James S. Nowick *
DOI:10.1021/jacs.4c17175delete
deleteOriginal
deleteShare
deleteSave
Abstract

Abstract

En 中文
Vancomycin continues to be a widely used antibiotic of last resort in treating drug-resistant pathogens despite the emergence of vancomycin-resistant strains such as vancomycin-resistant Enterococci (VRE). This communication reports that conjugation of vancomycin to a second antibiotic that targets a different region of lipid II enhances and rescues its antibiotic activity. Conjugation of vancomycin to a minimal teixobactin pharmacophore in which residues 1-6 are replaced with an aromatic amide results in substantial enhancement in activity over the individual components or mixtures thereof. Three conjugates with minimum inhibitory concentrations (MICs) of 0.5 mu g/mL against methicillin-resistant Staphylococcus aureus (MRSA) and 0.063-0.125 mu g/mL against methicillin-susceptible Staphylococcus aureus (MSSA) were identified. Each of these conjugates is also active against VRE, even though the individual components are inactive, with the most active conjugate (Cbp-Lys10-teixo7-11-vanco) having an MIC of 2-4 mu g/mL. These findings demonstrate that conjugation of vancomycin to a minimal teixobactin pharmacophore is an effective strategy for enhancing the activity of vancomycin against important Gram-positive pathogens.
Keywords:
ALA-D-ALA
RESISTANCE
MECHANISM
BINDING
IMPACT

Journal

Journal of the American Chemical Society cover
Journal of the American Chemical Society
IF:
15.6
Papers:
20.0W
Citations:
60.2W

Organization

U
Univ Calif Irvine
Scholars:
1.6K
Papers: 800
Citations: 401
Cited Papers

Cited Papers

errShare
errSave
Product Quality of Parenteral Vancomycin Products in the United States
err2012-06-01
err37
errOAAI
errNambiar, S.; Madurawe, R. D.; Zuk, S. M.; Khan, S. R.; Ellison, C. D.; Faustino, P. J.; Mans, D. J.; Trehy, M. L.; Hadwiger, M. E.; Boyne, M. T., II; Biswas, K.; Cox, E. M.
errShare
errSave
errShare
errSave
Teixobactin kills bacteria by a two-pronged attack on the cell envelope
err2022-08-03
err0
errOAAI
errRhythm Shukla; Francesca Lavore; Sourav Maity; Maik G. N. Derks; Chelsea R. Jones; Bram J. A. Vermeulen; Adéla Melcrová; Michael A. Morris; Lea Marie Becker; Xiaoqi Wang; Raj Kumar; João Medeiros-Silva; Roy A. M. van Beekveld; Alexandre M. J. J. Bonvin; Joseph H. Lorent; Moreno Lelli; James S. Nowick; Harold D. MacGillavry; Aaron J. Peoples; Amy L. Spoering; Losee L. Ling; Dallas E. Hughes; Wouter H. Roos; Eefjan Breukink; Kim Lewis; Markus Weingarth
errShare
errSave
Synthesis of Tridecaptin-Antibiotic Conjugates with in Vivo Activity against Gram-Negative Bacteria
err2015-12-04
err45
PREAI
errCochrane, Stephen A.; Li, Xuefeng; He, Sisi; Yu, Min; Wu, Min; Vederas, John C.
errShare
errSave
The Vancomycin−Nisin(1−12) Hybrid Restores Activity against Vancomycin Resistant Enterococci
err2008-11-07
err0
errOAAI
errChristopher J. Arnusch; Alexandre M. J. J. Bonvin; Anne Marie Verel; Wouter T. M. Jansen; Rob M. J. Liskamp; Ben de Kruijff; Roland J. Pieters; Eefjan Breukink
errShare
errSave
Gram-scale total synthesis of teixobactin promoting binding mode study and discovery of more potent antibiotics
err2019-07-22
err34
errOAAI
errZong, Yu; Fang, Fang; Meyer, Kirsten J.; Wang, Liguo; Ni, Zhihao; Gao, Hongying; Lewis, Kim; Zhang, Jingren; Rao, Yu
errShare
errSave
researcher View more